BioCardia Inc. Warrant (BCDAW)
$0.01
$0.00
(-1.61%)
As on 02-Aug-2024 16:00EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-77.42 Mln
EBITDA
$-97.36 Mln
Net Profit
$-101.86 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioCardia Inc. Warrant (BCDAW)
| -51.2 | -52.0 | -69.5 | -98.4 | -84.4 | -- | -- |
|
BSE Sensex*
| -9.4 | -1.8 | 2.6 | -3.9 | 5.8 | 5.9 | 10.4 |
|
Company
|
2023
|
|---|---|
|
BioCardia Inc. Warrant (BCDAW)
| -98.5 |
|
BSE Sensex
| 18.7 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout BioCardia Inc. Warrant (BCDAW)
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell... therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California. Read more
-
CEO, President & Director
Dr. Peter A. Altman Ph.D.
-
CEO, President & Director
Dr. Peter A. Altman Ph.D.
-
Headquarters
Sunnyvale, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BioCardia Inc. Warrant (BCDAW)
What is the current share price of BioCardia Inc Warrant (BCDAW) Today?
The share price of BioCardia Inc Warrant (BCDAW) is $0.01 (NASDAQ) as of 02-Aug-2024 16:00 EDT. BioCardia Inc Warrant (BCDAW) has given a return of -84.39% in the last 3 years.
What is the current PB & PE ratio of BioCardia Inc Warrant (BCDAW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
0.00 |
-0.01 |
2022 |
-1.27 |
3.10 |
2021 |
-1.50 |
1.83 |
2020 |
-1.70 |
1.33 |
2019 |
-0.40 |
2.48 |
What is the 52 Week High and Low of BioCardia Inc Warrant (BCDAW)?
The 52-week high and low of BioCardia Inc Warrant (BCDAW) are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of BioCardia Inc Warrant (BCDAW)?
BioCardia Inc Warrant (BCDAW) has a market capitalisation of -- as on 13-Aug-2024. As per SEBI classification, it is a company.
Should I invest in BioCardia Inc Warrant (BCDAW)?
Before investing in BioCardia Inc Warrant (BCDAW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.